inVentiv Health names Michael McKelvey EVP, Clinical division president
Global CRO inVentiv Health has appointed Michael McKelvey, Ph.D., president, inVentiv Health Clinical Division, and executive vice president, inVentiv Health. McKelvey is a seasoned veteran within the CRO industry and has a strong background in clinical development, technology and the development of innovative industry strategies. McKelvey has extensive experience in building and managing successful global organizations in the pharmaceutical services, healthcare, information technologies, life sciences, technology and global core laboratory industries.
"Mike McKelvey has proven himself to be a hands-on leader who builds dynamic teams to tackle some of the most critical drug development issues facing the industry," said Jeffrey P. McMullen, chairman, inVentiv Health Clinical Division, and vice chairman, inVentiv Health. "His vision is to incorporate innovation into the current drug development process by providing clients with an outsourcing model that embeds both clinical and commercial services."
Before joining inVentiv Health, McKelvey was executive vice president and chief operating officer at Aptiv Solutions, a global clinical development services company focused on adaptive clinical trial design. Aptiv Solutions was acquired by Icon in 2014. Previously, he was president and CEO and a board member of eResearchTechnology (ERT), a multi-product provider of clinical research services. McKelvey also led Parexel's phase II-IV clinical operations for the Americas, as well as their global data management and global biostatistics groups.
The inVentiv Health Clinical Leadership team, including Greg Skalicky, chief commercial officer, Rick Shimota, chief financial officer and Gregg Dearhammer, chief operating officer, will continue in their roles, supporting McKelvey to help achieve the organization's objectives.